Prestige Consumer Healthcare
About: Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Employees: 600
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 23
100% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]
7% more capital invested
Capital invested by funds: $4.1B [Q4 2024] → $4.4B (+$299M) [Q1 2025]
7% more funds holding
Funds holding: 334 [Q4 2024] → 356 (+22) [Q1 2025]
2.93% less ownership
Funds ownership: 106.18% [Q4 2024] → 103.25% (-2.93%) [Q1 2025]
31% less repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 153
79% less call options, than puts
Call options by funds: $9K | Put options by funds: $43K
Research analyst outlook
We haven’t received any recent analyst ratings for PBH.
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
GlobeNewsWire
3 weeks ago
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination
TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup (the “Product”) due to the presence of Bacillus cereus and loss of shelf-stability. Bacillus cereus (B. cereus) can cause two types of food-borne illnesses. One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food. Diarrhea may be a small volume or profuse and watery. Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.
Neutral
Zacks Investment Research
1 month ago
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
Neutral
GlobeNewsWire
1 month ago
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
Positive
Zacks Investment Research
1 month ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Positive
Zacks Investment Research
1 month ago
Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?
PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.
Positive
Zacks Investment Research
1 month ago
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Zacks Investment Research
1 month ago
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
Neutral
Seeking Alpha
2 months ago
Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q4 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Phil Terpolilli – Vice President, Investor Relations and Treasury Ron Lombardi – Chairman, President and Chief Executive Officer Christine Sacco – Chief Financial Officer and Chief Operating Officer Conference Call Participants Rupesh Parikh – Oppenheimer Susan Anderson – Canaccord Keith Devas – Jefferies Glenn West – William Blair Anthony Lebiedzinski – Sidoti & Company Doug Lane – Water Tower Research Operator Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
2 months ago
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charts implemented using Lightweight Charts™